resources

Lupin Ltd.

NSE: LUPIN

BSE: 500257

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,953.20-6.8 (-0.35%)

14 Oct, 12:00 AM

Overview Analysis Statements Technicals Forecast Peers Resources

News

Annual Reports and Financial Documents

Lupin Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2108
Annual Reports	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	—
Quarterly Results	—	—	—	—	—	—	Mar Jun Sept Dec	Mar Jun Sept Dec	Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun	Dec
Conference Calls	—	—	—	—	—	—	—	—	10Feb 25May 26Aug 10Nov	13Feb 25May 9Aug 16Nov	16Feb 16May 11Aug 17Nov	14Feb 14May 13Aug 13Nov	19Feb 21May 11Aug 12Nov	17Feb 14May 12Aug	—
Presentations	—	—	—	—	—	—	—	—	12Jan 28Jan 13May 11Aug 28Oct	12Jan 4Feb 19May 4Aug 10Nov	11Jan 10Feb 10May 4Aug 8Nov	8Feb 7May 6Aug 7Nov	12Feb 15May 6Aug 6Nov	12Feb 7May 6Aug 7Aug	—

Corporate Announcements and Regulatory Filings

Lupin Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20189 Oct 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.
Press Release / Media Release8 Oct 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP
Press Release / Media Release6 Oct 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Launches Formoflo-G MDI, World''s First Fixed-dose Triple Combination Drug for COPD Management.
General1 Oct 2026
Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines, Inc.
Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which MPPI has become a step-down wholly owned subsidiary of the Company effective ....
Closure of Trading Window28 Sept 2026
Closure of Trading Window
Intimation of Closure of Trading Window.
Press Release / Media Release28 Sept 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension.
Allotment of ESOP / ESPS21 Sept 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation of allotment of 24,111 equity shares under ESOP.
Analyst / Investor Meet8 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation about participating in the Analyst/Institutional Investors Meet.
Press Release / Media Release4 Sept 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.
General28 Aug 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating
ESG Rating by Crisil ESG Ratings & Analytics Ltd.
Allotment of ESOP / ESPS25 Aug 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation of allotment of 30967 equity shares under ESOP.
General24 Aug 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
ESG Rating by ESG Risk Assessment and Insights Limited.
General20 Aug 2026
Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.
VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.
Demise18 Aug 2026
Announcement under Regulation 30 (LODR)-Demise
Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.
Press Release / Media Release17 Aug 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.
Press Release / Media Release10 Aug 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
Analyst / Investor Meet10 Aug 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation about participating in the Analyst/Institutional Investors Meet.
Newspaper Publication8 Aug 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Analyst / Investor Meet7 Aug 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Link of Audio recording of the Earnings Call-Q1 FY27.
Press Release / Media Release6 Aug 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Q1 FY2027 Results

Frequently Asked Questions

Where can I download the annual report of Lupin Ltd.?

Annual reports of Lupin Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.

Where can I find the quarterly results of Lupin Ltd.?

Quarterly earnings results and presentations of Lupin Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.

Does Lupin Ltd. publish earnings call transcripts?

Earnings call transcripts of Lupin Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.

Where can I find investor presentations of Lupin Ltd.?

Investor presentations and annual day presentations of Lupin Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.

What are the recent corporate announcements of Lupin Ltd.?

Corporate announcements and regulatory filings of Lupin Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.

How do I access the regulatory filings of Lupin Ltd.?

Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Lupin Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.

What is the ISIN of Lupin Ltd.?

The ISIN (International Securities Identification Number) of Lupin Ltd. is INE326A01037. This is the unique identifier used across exchanges and depositories.

On which stock exchange is Lupin Ltd. listed?

Lupin Ltd. is listed on NSE and BSE. The NSE symbol is LUPIN and the BSE code is -.

Where can I find the shareholding pattern of Lupin Ltd.?

The quarterly shareholding pattern of Lupin Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.

How current is the data for Lupin Ltd. on Sharpely?

Share price data for Lupin Ltd. is updated as of 14 Oct 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.